Slide 1: EBOS Group Limited
mer BOS GROUP LIMITED
Slide 2: Disclaimer
DISCLAIMER The information in this presentation was prepared by EBOS Group Limited (“EBOS” or the “Group”) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and, to the extent permitted by law, no representation is made as to
Slide 3: Executive Summary
EXECUTIVE SUMMARY • Ongoing organic growth driven by ~$385m revenue from new pharmacy wholesale customers and double-digit growth in Southeast Asia within Medical Technology, with total underlying Group EBITDA Solid FY25 growth of 7.5% (excl. CWA)1 performance • Disciplined cost management, deliveri
Slide 4: FY25 Performance
FY25 PERFORMANCE FY25 result in line with guidance, reflecting strong Underlying growth1, supported by strategy execution Revenue Underlying EBITDA Underlying EPS $12,267m $585m 131.3 cps +12.0% excl. CWA1 +7.5% excl. CWA1 Statutory Revenue Statutory EBITDA Statutory EPS $12,267m $556m 109.7 cps (-7
Slide 5: Division Highlights
DIVISION HIGHLIGHTS Solid organic growth across both Healthcare and Animal Care segments, supplemented with strategic acquisitions Community Pharmacy Institutional Healthcare Contract Logistics Animal Care • ~$540m annualised revenue from • Continued strong growth in • New customer growth in Austral
Slide 6: Near-Term Growth Objectives Achieved
NEAR-TERM GROWTH OBJECTIVES ACHIEVED Continued delivery against strategy with all initiatives achieved Progress to date Status Base business growth Healthcare and Animal Care segments to record positive organic growth, excluding the CWA contract Underlying EBITDA growth for Healthcare and Animal Car
Slide 7: Environmental, Social, Governance Program
ENVIRONMENTAL, SOCIAL, GOVERNANCE PROGRAM We recognise our responsibility as a provider of essential network infrastructure, products, and services to improving both human and animal health outcomes. Our sustainability pillars ESG highlights • Progressed toward generating renewable electricity to ma
Slide 8: Healthcare Results
Healthcare Results
Slide 9: Healthcare Segment
HEALTHCARE SEGMENT A strong performance (ex. CWA1), supported by customer wins and strategic acquisitions Var% $m FY25 FY24 Var% ex CWA1 • Australian Healthcare business grew revenue by 12.9% and Underlying Revenue 11,593 12,610 (8.1%) 11.8% EBITDA by 5.9% (ex. CWA1) led by Community Pharmacy, TWC,
Slide 10: Community Pharmacy
COMMUNITY PHARMACY A leading pharmaceutical wholesaler in Australia and New Zealand • Revenue and GOR increased by 15.8% and 7.0% Var% $m FY25 FY24 Var% ex CWA1 (ex. CWA1) respectively, driven by: Revenue 6,456 7,810 (17.3%) 15.8% - Pharmacy wholesale growth from both existing GOR 588 678 (13.3%) 7.
Slide 11: TerryWhite Chemmart
TerryWhite Chemmart1 The leading health-services focussed community pharmacy network in Australia, administering ~1 million vaccinations and filling ~1.2 million prescription transactions online in FY25 • Added 34 net new stores to TWC’s national network, continuing its impressive growth in pharmacy
Slide 12: Institutional Healthcare
INSTITUTIONAL HEALTHCARE Australia and New Zealand’s leading hospital medicines wholesaler and one of ANZ and Southeast Asia’s leading medical technology distributors Revenue and GOR ($m) • Revenue and GOR increased by 8.4% and 11.4% 680 respectively 570 611 • Medicines, consumables and other revenu
Slide 13: Contract Logistics
CONTRACT LOGISTICS One of ANZ’s leading healthcare-focussed contract logistics providers GOR ($m) • GOR was up 3.3% on the prior period, driven by: - New customer growth in Australia and New Zealand, enabled by new warehouse capacity installed over last two years 153 149 154 129 92 - Australian GOR
Slide 14: Animal Care Results
Animal Care Results
Slide 15: Animal Care Segment
ANIMAL CARE SEGMENT ANZ’s largest dry dog food brand1 in pet specialty and ANZ’s leading vet wholesaler $m FY25 FY24 Var% • Revenue and EBITDA increased by 16.3% and 10.4% respectively, supported Revenue 673 579 16.3% by the branded business and the acquisition of SVS. Excluding SVS, revenue and EBI
Slide 16: Acquisition of Next Generation Pet Foods
ACQUISITION OF NEXT GENERATION PET FOODS1 Provides expansion into new high growth, high value products, and expands manufacturing capability • A Queensland based manufacturer and supplier of multi-format pet treats, with two facilities dedicated to manufacturing, packaging, order assembly and dispat
Slide 17: Financial
Financial aixelanalelutela
Slide 18: Group Performance
GROUP PERFORMANCE The Group delivered strong revenue and Underlying EBITDA growth (excl. CWA)1 of 12.0% and 7.5% respectively Var% • Revenue increased by 12.0% (excl. CWA)1, supported by both $m FY25 FY24 Var% ex CWA1 Healthcare and Animal Care segments Underlying results2 Revenue 12,267 13,189 (7.0
Slide 19: Cash Flow
CASH FLOW Strong cash generation Cashflow ($m) FY25 FY24 Var$ • Cash flow before capex of $448m, supported organic growth Underlying EBITDA 585 624 (39) agenda, M&A strategy, shareholder returns and balance sheet Net interest (106) (94) (13) management Tax (82) (104) 21 • Cash conversion days of 18
Slide 20: Organic Capital: DC Renewal Program Concludes in 2026
ORGANIC CAPITAL: DC RENEWAL PROGRAM CONCLUDES IN 2026 • DC renewal program has also achieved: Increased Healthcare distribution capacity over FY23-26 - Additional refrigeration footprint, that has already enabled GLP-1 customer growth 2023 2024 2025 2026 - Operating efficiency gains, with automation
Slide 21: Acquisitions
ACQUISITIONS Delivering value accretive M&A • Five1,4 investments executed for total consideration of $210 million, and are expected to generate $330 million of revenue on a full year basis • Acquisitions focused on building scale in core businesses and expanding presence across key channels and geo
Slide 22: Balance Sheet
BALANCE SHEET Balance sheet and overall liquidity remains strong following debt refinancing and completion of capital raise Net debt and Leverage ratio1 • Net debt of $918m, reduced by $101m, following successful completion of a $254m capital raise in April 2025 to fund bolt-on 1.94x 1.89x 1.92x 1.5
Slide 23: Earnings and Dividends
EARNINGS AND DIVIDENDS Aligning shareholder returns with earnings growth Underlying Earnings per Share (cents) • Underlying EPS of 131.3 cents, reflecting growth of Underlying business partially offsetting loss of CWA contract 147.9 157.9 129.5 131.3 • Final dividend of NZ 61.5 cents per share, brin
Slide 24: Near-Term Growth and Outlook
| eat ESSkne = rm eto ask EES S| SBay B RESRSA Sm sa ai = ee eee Near-Term Growth and Outlook
Slide 25: FY26 Outlook
FY26 OUTLOOK • Continued positive healthcare and animal care industry trends to support growth Market dynamics • Near-term macro pressures include: competitive wholesale pharmacy environment, soft hospital capital spend, and subdued consumer sentiment impacting discretionary pet categories • Targeti
Slide 26: Investment Proposition
INVESTMENT PROPOSITION A defensive growth care business underpinned by long-term industry trends, leading positions and strong capabilities Increased pharma and Pet Ageing population Pet ownership medical spend humanisation Macro trends Increased healthcare spend Increased pet spend Australia and Ne
Slide 27: Supporting Information
Supporting Information
Slide 28: Segment Information
SEGMENT INFORMATION First Half Second Half Full Year Revenue GOR Revenue GOR Revenue GOR 1 1 1 1 1 $m FY25 FY24 Var% FY25 FY24 Var% FY25 FY24 Var% FY25 FY24 Var% FY25 FY24 Var% FY25 FY241 Var% Healthcare Community Pharmacy 3,144 2,802 12.2% 288 276 4.6% 3,312 2,771 19.5% 299 273 9.5% 6,456 5,574 15.
Slide 29: Reconciliation of Statutory to Underlying Results
RECONCILIATION OF STATUTORY TO UNDERLYING RESULTS FY25 FY24 $m Revenue EBITDA EBIT PBT NPAT Revenue EBITDA EBIT PBT NPAT Statutory result 12,267 556 409 302 215 13,189 606 477 383 272 M&A transaction costs - 11 11 11 10 - 10 10 10 7 Restructuring & site transition costs - 18 18 18 13 - 9 9 9 6 PPA a
Slide 30: Segment EBITDA and EBIT Reconciliation
SEGMENT EBITDA AND EBIT RECONCILIATION EBITDA EBIT $m FY25 FY24 Var % FY25 FY24 Var% Healthcare Statutory 472 537 (12.2%) 339 420 (19.3%) Add M&A transaction costs 10 2 10 2 Add Restructuring & site transition costs 18 9 18 9 Add PPA amortisation (non-cash) - - 27 26 Total underlying earnings adjust
Slide 31: Glossary of Terms and Measures
GLOSSARY OF TERMS AND MEASURES Except where noted, common terms and measures used in this document are based upon the following definitions: Term Definition Revenue Revenue from the sale of goods and the rendering of services Gross Operating Revenue (GOR) Revenue less cost of sales and the write-dow
Slide 32: www.ebosgroup.com
mer BOS GROUP LIMITED www.ebosgroup.com